The role of human rhinovirus in immunology, COPD, and corresponding treatments

Frontiers in Biology

Volumn 8, Issue 4, 2013, Pages 377-386

  Roberts, William J ^a,b   Sergakis, Georgianna G ^b   Zuo, Li ^a,b  

^a OAKLAND UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

common cold; COPD; human rhinovirus; immunology

Indexed keywords

HUMAN RHINOVIRUS SP.; RHINOVIRUS;

EID: 84881024228     PISSN: 16747984     EISSN: 16747992     Source Type: Journal    
DOI: 10.1007/s11515-013-1264-0     Document Type: Review

References (98)

1. Alper CM, Doyle WJ, Skoner D P, Buchman C A, Cohen S, Gwaltney J M (1998). Prechallenge antibodies moderate disease expression in adults experimentally exposed to rhinovirus strain hanks. Clin Infect Dis, 27(1): 119-128.
2. Alper C M, Doyle W J, Skoner D P, Buchman C A, Seroky J T, Gwaltney J M, Cohen S A (1996). Prechallenge antibodies: moderators of infection rate, signs, and symptoms in adults experimentally challenged with rhinovirus type 39. Laryngoscope, 106(10): 1298-1305.
3. Andries K, Dewindt B, Snoeks J, Wouters L, Moereels H, Lewi P J, Janssen P A (1990). Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol, 64(3): 1117-1123.
4. Arruda E, Pitkäranta A, Witek T J Jr, Doyle C A, Hayden F G (1997). Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol, 35(11): 2864-2868.
5. Barral P M, Sarkar D, Fisher P B, Racaniello V R (2009). RIG-I is cleaved during picornavirus infection. Virology, 391(2): 171-176.
6. Bella J, Rossmann M G (2000). ICAM-1 receptors and cold viruses. Pharm Acta Helv, 74(2-3): 291-297.
7. Binford S L, Maldonado F, Brothers M A, Weady P T, Zalman L S, Meador J W 3rd, Matthews D A, Patick A K (2005). Conservation of amino acids in human rhinovirus 3C protease correlates with broadspectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother, 49(2): 619-626.
8. Bochkov Y A, Palmenberg A C, Lee WM, Rathe J A, Amineva S P, Sun X, Pasic T R, Jarjour N N, Liggett S B, Gern J E (2011). Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nat Med, 17(5): 627-632.
9. Brabec M, Schober D, Wagner E, Bayer N, Murphy R F, Blaas D, Fuchs R (2005). Opening of size-selective pores in endosomes during human rhinovirus serotype 2 in vivo uncoating monitored by single-organelle flow analysis. J Virol, 79(2): 1008-1016.
10. Brabec-Zaruba M, Pfanzagl B, Blaas D, Fuchs R (2009). Site of human rhinovirus RNA uncoating revealed by fluorescent in situ hybridization. J Virol, 83(8): 3770-3777.
11. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C, and the TRial of Inhaled STeroids and long-acting beta2 agonists study group (2003). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361(9356): 449-456.
12. Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, ZuWallack R L, Menjoge S S, Serby C W, Witek T Jr (2002). A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J, 19(2): 217-224.
13. Colonno R J, Callahan P L, Long W J (1986). Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol, 57(1): 7-12.
14. De Palma A M, Vliegen I, De Clercq E, Neyts J (2008). Selective inhibitors of picornavirus replication. Med Res Rev, 28(6): 823-884.
15. Di Pierro F, Rapacioli G, Ferrara T, Togni S (2012). Use of a standardized extract from Echinacea angustifolia (Polinacea) for the prevention of respiratory tract infections. Altern Med Rev, 17(1): 36-41.
16. Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A (2002). Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 57(10): 847-852.
17. Douglas R M, Hemilä H, Chalker E, Treacy B (2007). Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev, (3): CD000980.
18. Douglass J A, Dhami D, Gurr C E, Bulpitt M, Shute J K, Howarth P H, Lindley I J, Church M K, Holgate S T (1994). Influence of interleukin-8 challenge in the nasal mucosa in atopic and nonatopic subjects. Am J Respir Crit Care Med, 150(4): 1108-1113.
19. Drahos J, Racaniello V R (2009). Cleavage of IPS-1 in cells infected with human rhinovirus. J Virol, 83(22): 11581-11587.
20. Edwards M R, Hewson C A, Laza-Stanca V, Lau H T, Mukaida N, Hershenson M B, Johnston S L (2007). Protein kinase R, IkappaB kinase-beta and NF-kappaB are required for human rhinovirus induced pro-inflammatory cytokine production in bronchial epithelial cells. Mol Immunol, 44(7): 1587-1597.
21. Fashner J, Ericson K, Werner S (2012). Treatment of the common cold in children and adults. Am Fam Physician, 86(2): 153-159.
22. Fehniger T A, Caligiuri M A (2001). Interleukin 15: biology and relevance to human disease. Blood, 97(1): 14-32.
23. Fraenkel D J, Bardin P G, Sanderson G, Lampe F, Johnston S L, Holgate S T (1995). Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med, 151(3 Pt 1): 879-886.
24. Fuchs R, Blaas D (2010). Uncoating of human rhinoviruses. Rev Med Virol, 20(5): 281-297.
25. Gavala M L, Bertics P J, Gern J E (2011). Rhinoviruses, allergic inflammation, and asthma. Immunol Rev, 242(1): 69-90.
26. Giranda V L, Heinz B A, Oliveira MA, Minor I, Kim K H, Kolatkar P R, Rossmann M G, Rueckert R R (1992). Acid-induced structural changes in human rhinovirus 14: possible role in uncoating. Proc Natl Acad Sci USA, 89(21): 10213-10217.
27. Gwaltney J M Jr, Hendley J O, Simon G, Jordan W S Jr (1967). Rhinovirus infections in an industrial population. II. Characteristics of illness and antibody response. JAMA, 202(6): 494-500.
28. Haghighat A, Svitkin Y, Novoa I, Kuechler E, Skern T, Sonenberg N (1996). The eIF4G-eIF4E complex is the target for direct cleavage by the rhinovirus 2A proteinase. J Virol, 70(12): 8444-8450.
29. Harris J M 2nd, Gwaltney J M Jr (1996). Incubation periods of experimental rhinovirus infection and illness. Clin Infect Dis, 23(6): 1287-1290.
30. Hayden F G, Gwaltney J M Jr, Colonno R J (1988). Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res, 9(4): 233-247.
31. Hemilä H (1996). Vitamin C and common cold incidence: a review of studies with subjects under heavy physical stress. Int J Sports Med, 17(5): 379-383.
32. Hemilä H (1997). Vitamin C intake and susceptibility to the common cold. Br J Nutr, 77(1): 59-72.
33. Hendley J O, Gwaltney J M Jr (1988). Mechanisms of transmission of rhinovirus infections. Epidemiol Rev, 10: 243-258.
34. Hewson C A, Jardine A, Edwards M R, Laza-Stanca V, Johnston S L (2005). Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J Virol, 79(19): 12273-12279.
35. Jakiela B, Brockman-Schneider R, Amineva S, Lee W M, Gern J E (2008). Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol, 38(5): 517-523.
36. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S (2005). Cell type-specific involvement of RIG-I in antiviral response. Immunity, 23(1): 19-28.
37. Kaul P, Biagioli M C, Singh I, Turner R B (2000). Rhinovirus-induced oxidative stress and interleukin-8 elaboration involves p47-phox but is independent of attachment to intercellular adhesion molecule-1 and viral replication. J Infect Dis, 181(6): 1885-1890.
38. Kelly J T, Busse W W (2008). Host immune responses to rhinovirus: Mechanisms in asthma. J Allergy Clin Immunol, 122: 671-682; quiz 683-674.
39. Kennedy J L, Turner R B, Braciale T, Heymann P W, Borish L (2012). Pathogenesis of rhinovirus infection. Curr Opin Virol, 2(3): 287-293.
40. Khan A G, Pichler J, Rosemann A, Blaas D (2007). Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH. J Virol, 81(9): 4625-4632.
41. Kim J, Sanders S P, Siekierski E S, Casolaro V, Proud D (2000). Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection. J Immunol, 165(6): 3384-3392.
42. Kim W K, Gern J E (2012). Updates in the relationship between human rhinovirus and asthma. Allergy Asthma Immunol Res, 4(3): 116-121.
43. Ko FW, Ip M, Chan P K, Ng S S, Chau S S, Hui D S (2008). A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med, 102(8): 1109-1116.
44. Laine P, Blomqvist S, Savolainen C, Andries K, Hovi T (2006). Alignment of capsid protein VP1 sequences of all human rhinovirus prototype strains: conserved motifs and functional domains. J Gen Virol, 87(Pt 1): 129-138.
45. Levandowski R A, Ou D W, Jackson G G (1986). Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J Infect Dis, 153(4): 743-748.
46. Liebig H D, Ziegler E, Yan R, Hartmuth K, Klump H, Kowalski H, Blaas D, Sommergruber W, Frasel L, Lamphear B, et al (1993). Purification of two picornaviral 2A proteinases: interaction with eIF-4 gamma and influence on in vitro translation. Biochemistry, 32(29): 7581-7588.
47. Lopez-Souza N, Dolganov G, Dubin R, Sachs L A, Sassina L, Sporer H, Yagi S, Schnurr D, Boushey H A, Widdicombe J H (2004). Resistance of differentiated human airway epithelium to infection by rhinovirus. Am J Physiol Lung Cell Mol Physiol, 286(2): L373-L381.
48. Mallia P, Message S D, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards M R, Slater L, Papi A, Stanciu L A, Kon O M, Johnson M, Johnston S L (2011). Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med, 183(6): 734-742.
49. Mallia P, Message S D, Kebadze T, Parker H L, Kon O M, Johnston S L (2006). An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res, 7(1): 116.
50. Marlin S D, Staunton D E, Springer T A, Stratowa C, Sommergruber W, Merluzzi V J (1990). A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature, 344(6261): 70-72.
51. McManus T E, Marley A M, Baxter N, Christie S N, O'Neill H J, Elborn J S, Coyle P V, Kidney J C (2008). Respiratory viral infection in exacerbations of COPD. Respir Med, 102(11): 1575-1580.
52. Message S D, Johnston S L (2001). The immunology of virus infection in asthma. Eur Respir J, 18(6): 1013-1025.
53. Mukaida N, Okamoto S, Ishikawa Y, Matsushima K (1994). Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol, 56(5): 554-558.
54. Müller-Jakic B, Breu W, Pröbstle A, Redl K, Greger H, Bauer R (1994). In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from Echinacea and Achillea species. Planta Med, 60(1): 37-40.
55. Newcomb D C, Sajjan U, Nanua S, Jia Y, Goldsmith A M, Bentley J K, Hershenson M B (2005). Phosphatidylinositol 3-kinase is required for rhinovirus-induced airway epithelial cell interleukin-8 expression. J Biol Chem, 280(44): 36952-36961.
56. Niewoehner D E (2002). The role of systemic corticosteroids in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Med, 1(4): 243-248.
57. Olson N H, Kolatkar P R, Oliveira M A, Cheng R H, Greve J M, McClelland A, Baker T S, Rossmann M G (1993). Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci USA, 90(2): 507-511.
58. Papadopoulos N G, Bates P J, Bardin P G, Papi A, Leir S H, Fraenkel D J, Meyer J, Lackie P M, Sanderson G, Holgate S T, Johnston S L (2000). Rhinoviruses infect the lower airways. J Infect Dis, 181(6): 1875-1884.
59. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri L M, Johnston S L (2006). Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med, 173(10): 1114-1121.
60. Papi A, Contoli M, Gasparini P, Bristot L, Edwards MR, Chicca M, Leis M, Ciaccia A, Caramori G, Johnston S L, Pinamonti S (2008). Role of xanthine oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. J Biol Chem, 283(42): 28595-28606.
61. Papi A, Papadopoulos N G, Stanciu L A, Bellettato C M, Pinamonti S, Degitz K, Holgate S T, Johnston S L (2002). Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells. FASEB J, 16(14): 1934-1936.
62. Pappas D E, Hendley J O, Hayden F G, Winther B (2008). Symptom profile of common colds in school-aged children. Pediatr Infect Dis J, 27(1): 8-11.
63. Patick A K, Brothers M A, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith G J 3rd, Zalman L S, Burns-Naas L A, Tran J Q (2005). In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother, 49(6): 2267-2275.
64. Potena A, Caramori G, Casolari P, Contoli M, Johnston S L, Papi A (2007). Pathophysiology of viral-induced exacerbations of COPD. Int J Chron Obstruct Pulmon Dis, 2(4): 477-483.
65. Prchla E, Plank C, Wagner E, Blaas D, Fuchs R (1995). Virus-mediated release of endosomal content in vitro: different behavior of adenovirus and rhinovirus serotype 2. J Cell Biol, 131(1): 111-123.
66. Rabin R L, Park M K, Liao F, Swofford R, Stephany D, Farber J M (1999). Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol, 162(7): 3840-3850.
67. Retamales I, Elliott W M, Meshi B, Coxson H O, Pare P D, Sciurba F C, Rogers R M, Hayashi S, Hogg J C (2001). Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med, 164(3): 469-473.
68. Rollinger J M, Schmidtke M (2011). The human rhinovirus: humanpathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev, 31(1): 42-92.
69. Sajjan U S, Jia Y, Newcomb D C, Bentley J K, Lukacs NW, LiPuma J J, Hershenson M B (2006). H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J, 20(12): 2121-2123.
70. Sasazuki S, Sasaki S, Tsubono Y, Okubo S, Hayashi M, Tsugane S (2006). Effect of vitamin C on common cold: randomized controlled trial. Eur J Clin Nutr, 60(1): 9-17.
71. Savolainen-Kopra C, Korpela T, Simonen-Tikka M L, Amiryousefi A, Ziegler T, Roivainen M, Hovi T (2012). Single treatment with ethanol hand rub is ineffective against human rhinovirus-hand washing with soap and water removes the virus efficiently. J Med Virol, 84(3): 543-547.
72. Schneider W J, Nimpf J (2003). LDL receptor relatives at the crossroad of endocytosis and signaling. Cell Mol Life Sci, 60(5): 892-903.
73. Science M, Johnstone J, Roth D E, Guyatt G, Loeb M (2012). Zinc for the treatment of the common cold: a systematic review and metaanalysis of randomized controlled trials. CMAJ, 184(10): E551-E561.
74. Skern T, Torgersen H, Auer H, Kuechler E, Blaas D (1991). Human rhinovirus mutants resistant to low pH. Virology, 183(2): 757-763.
75. Slater L, Bartlett NW, Haas J J, Zhu J, Message S D, Walton R P, Sykes A, Dahdaleh S, Clarke D L, Belvisi M G, Kon O M, Fujita T, Jeffery P K, Johnston S L, Edwards M R (2010). Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog, 6(11): e1001178.
76. Snyers L, Zwickl H, Blaas D (2003). Human rhinovirus type 2 is internalized by clathrin-mediated endocytosis. J Virol, 77(9): 5360-5369.
77. Sommergruber W, Ahorn H, Klump H, Seipelt J, Zoephel A, Fessl F, Krystek E, Blaas D, Kuechler E, Liebig H D, Skern T (1994). 2A proteinases of coxsackie- and rhinovirus cleave peptides derived from eIF-4 gamma via a common recognition motif. Virology, 198(2): 741-745.
78. Strickland D K, Gonias S L, Argraves W S (2002). Diverse roles for the LDL receptor family. Trends Endocrinol Metab, 13(2): 66-74.
79. Sullivan S D, Ramsey S D, Lee T A (2000). The economic burden of COPD. Chest, 117(2 Suppl): 5S-9S.
80. Triantafilou K, Vakakis E, Richer E A, Evans G L, Villiers J P, Triantafilou M (2011). Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. Virulence, 2(1): 22-29.
81. Turner R B (2001). The treatment of rhinovirus infections: progress and potential. Antiviral Res, 49(1): 1-14.
82. Turner R B, Hendley J O (2005). Virucidal hand treatments for prevention of rhinovirus infection. J Antimicrob Chemother, 56(5): 805-807.
83. Turner R B, Hendley J O, Gwaltney J M Jr (1982). Shedding of infected ciliated epithelial cells in rhinovirus colds. J Infect Dis, 145(6): 849-853.
84. Turner R B, Wecker M T, Pohl G, Witek T J, McNally E, St George R, Winther B, Hayden F G (1999). Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA, 281(19): 1797-1804.
85. Turner R B, Weingand K W, Yeh C H, Leedy D W (1998). Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds. Clin Infect Dis, 26(4): 840-846.
86. Tyrrell D A, Cohen S, Schlarb J E (1993). Signs and symptoms in common colds. Epidemiol Infect, 111(1): 143-156.
87. Uncapher C R, DeWitt C M, Colonno R J (1991). The major and minor group receptor families contain all but one human rhinovirus serotype. Virology, 180(2): 814-817.
88. Vlasak M, Roivainen M, Reithmayer M, Goesler I, Laine P, Snyers L, Hovi T, Blaas D (2005). The minor receptor group of human rhinovirus (HRV) includes HRV23 and HRV25, but the presence of a lysine in the VP1 HI loop is not sufficient for receptor binding. J Virol, 79(12): 7389-7395.
89. Wang Q, Nagarkar D R, Bowman E R, Schneider D, Gosangi B, Lei J, Zhao Y, McHenry C L, Burgens R V, Miller D J, Sajjan U, Hershenson M B (2009). Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. J Immunol, 183(11): 6989-6997.
90. Wat D, Gelder C, Hibbitts S, Cafferty F, Bowler I, Pierrepoint M, Evans R, Doull I (2008). The role of respiratory viruses in cystic fibrosis. J Cyst Fibros, 7(4): 320-328.
91. Wilkinson T M, Hurst J R, Perera W R, Wilks M, Donaldson G C, Wedzicha J A (2006). Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest, 129(2): 317-324.
92. Winther B, Arruda E, Witek T J, Marlin S D, Tsianco M M, Innes D J, Hayden F G (2002). Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection. Arch Otolaryngol Head Neck Surg, 128(2): 131-136.
93. Winther B, Greve J M, Gwaltney J M Jr, Innes D J, Eastham J R, McClelland A, Hendley J O (1997). Surface expression of intercellular adhesion molecule 1 on epithelial cells in the human adenoid. J Infect Dis, 176(2): 523-525.
94. Winther B, McCue K, Ashe K, Rubino J R, Hendley J O (2007). Environmental contamination with rhinovirus and transfer to fingers of healthy individuals by daily life activity. J Med Virol, 79(10): 1606-1610.
95. Xing L, Casasnovas J M, Cheng R H (2003). Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptor-mediated virus uncoating. J Virol, 77(11): 6101-6107.
96. Xing L, Tjarnlund K, Lindqvist B, Kaplan G G, Feigelstock D, Cheng R H, Casasnovas J M (2000). Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J, 19(6): 1207-1216.
97. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo Y M, Gale M Jr, Akira S, Yonehara S, Kato A, Fujita T (2005). Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol, 175(5): 2851-2858.
98. Zalman L S, Brothers MA, Dragovich P S, Zhou R, Prins T J, Worland S T, Patick A K (2000). Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother, 44(5): 1236-1241.